
usd feb pm et
summari compani develop provid research product servic analysi
genet variat function
price-to-earnings oper ep
risk assess reflect high depend
rapid technolog advanc maintain market
share impact amount custom
depend govern fund buy
product risk somewhat balanc
domin market share dna sequenc industri
sticki custom profil grow
proport consum revenu tend
recur less volatil instrument revenu
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
revenu grew yoy materi
slowdown yoy month
end consum sale
slow growth yoy first
month slowdown
unexpect howev two year
launch novaseq line
launch tend drive cyclic
sale rapid sale gain also becom
difficult maintain given tremend
full-year revenu growth
expect growth slow
continu shine oper though
excel margin improv gross
margin increas
sg expens margin fell
period overal
think part impress margin
improv strong price power
best-in-class sequenc instrument
well harvest signific plant
machineri invest expect
margin improv less
capital-expenditure invest slow
think maintain lead
rapidli grow dna sequenc market
justifi premium valuat peer
yet cautiou price-to-earnings multipl
appear expens us even consid
robust growth outlook improv
margin note stock histori
rapid gain new instrument uptak
cycl hiseq hiseq
follow sluggish period
growth expect cool think may
occur novaseq system mark
two-year anniversari sale growth
risk view upsid sustain
novaseq shipment growth rather
cyclic slowdown instrument sale
next new system launch
better-than-expect growth consum
sale downsid risk signific cut
govern fund research lab
target ep estim
long-term forward price-to-earnings averag
due slow growth note novaseq
growth cycl produc sale growth
previou upgrad cycl think
warrant lower valuat
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice presid
global qualiti
corpor overview develop research tool large-scal analysi genet variat
function account physic differ among human eye color height
genet variat also import medic consequ includ predisposit diseas
differenti respons drug tool assist research autom billion test necessari
collect raw genet data imbed dna sequenc contain everi live cell
scientist use data investig dna sequenc dictat biolog event molecular
scale develop inform medic valuabl applic field studi known
genom rapidli expand given potenti custom diagnos treatment
improv drug therapi cure diseas
corpor strategi import aspect ilmn busi understand relationship
dna sequenc machin instrument consum instrument perman fixtur
laboratori larg up-front cost ilmn power dna sequenc machin novaseq
releas januari cost roughli per unit convers consum lower-cost
prepar kit scientist arrang test sampl feed machin run dna
sequenc test product relationship somewhat analog razor razor blade model
lab typic purchas small number instrument continu order larg volum
consum life machin run thousand sequenc test way singl
instrument sale lead durabl long-term sale consum
last decad ilmn annual sale growth follow cyclic trend relat new instrument
launch five-quart stretch year-over-year sale growth averag coincid launch
hiseq sequenc machin hiseq launch produc five
quarter growth averag new instrument ramp growth tend slower
expans ilmn instal base instrument field new product launch actual
reduc cyclic howev higher baselin recur consum servic demand
establish ilmn contribut sale instrument fallen
view trend favor consum carri higher margin addit lower
januari introduc novaseq system line think could reduc cost
sequenc within year note year-over-year instrument sale
fell posit growth neg june quarter howev event typic occur near
peak total sale growth expect ilmn cyclic sale growth slow lower novaseq
product cycl howev due larger sale mix consum versu previou cycl
market profil signific custom concentr tool servic use
research govern univers lab well commerci pharmaceut biotechnolog
agrigenom diagnost lab around world custom increas util
ilmn tool servic genom field rapidli develop first half geograph
composit year-over-year growth respect ilmn total sale unit state total
sequenc technolog continu advanc cost sequenc singl genom entir set
dna data contain cell continu fall accord nation institut cost
sequenc genom took sever week versu around sever
hour reduc time cost allow increas number entrant appli
genom market accord cb insight juli global fund genom startup
alreadi surpass record set pace doubl full-year
expect particip increasingli util sequenc tool servic effort develop
clinic commerci genom applic
competit landscap competit landscap intens sever larger
diversifi publicly-trad compani industri well numer emerg privat compani
publicly-trad compani includ thermo fisher scientif acquir main competitor life
technolog februari agil amersham bioscienc subsidiari ge
undisput leader next gener sequenc system howev market share
estim compani sizabl instal base system like ilmn hold
competit advantag emerg compani view instal system drive
persist sale consum product util consist invest innov
also transit one system anoth costli time-consum given requir train
new system level integr sequenc instrument laboratori work flow
financi trend sale growth driven robust uptak ilmn new sequenc system
turn increas instal instrument base turn lead higher consum sale sale
increas year end june compound annual growth rate
compound-annual-growth-rate perid earn tax amort increas
compound-annual-growth-rate adjust ep increas compound-annual-growth-rate illumina
conserv capit net debt neg ebita/net interest june
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc decemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
budget nation institut
nih grew rapidli last three year
materi increas fund academ
govern lab turn drive sale
growth lst compani gener
materi portion revenu lab
fy nih budget grew
fy
budget increas aid lst
sub-industri sale growth
forecast
expect anoth materi nih budget
increas fy support robust
demand sub-industri product
year ahead well
addit public-fund health care
research expect larg increas privat
biopharmaceut spend drive sale
growth life scienc tool servic
sub-industri month end septemb
estim spend
increas year-over-year
spend biotech
depart research tool product
well contract research servic
 growth continu year ahead
translat continu solid sale growth
lst sub-industri
care research type prolifer
around world particularli china
emerg market turn
drive strong intern sale growth
establish life scienc tool servic
compani china particular
view howev tailwind may moder
china face slowdown econom
growth use five largest compani
lst sub-industri proxi estim
averag growth sub-industri
china-deriv sale slow
year-over-year
long-term though think china
major emerg market nation like india
need continu rapidli increas health care
expenditur parallel grow
middl class turn like continu
support strong sale growth lst
sub-industri see happen despit
potenti neg impact
import/export tariff limit
large-scal supplier option
state-of-the-art lst product outsid
compani notabl except
switzerland-bas roch
 life
rise
 life
drop
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep buy opinion share inc
rais target price peer
forward ep estim within five year rang
ep vs ahead estim rais
ep estim ep estim
sale rose well forecast sale growth broad-bas
product growth across consum servic well geograph growth
consum servic account sale compar
year ago aid gross margin improv basi point howev
instrument sale fell compar year ago sequenc instrument
grew last quarter encourag robust growth genom
inform believ demand expand research market
within clinic consum market see well posit
captur signific portion market growth /jeffrey loo cfa
et cfra reiter buy opinion share inc
rais target price
peer ep estim within five
year rang rais ep estim ep
vs ahead estim sale rose well
growth forecast robust demand consum particularli
novaseq consum grew sequenti year ago
sequenc instrument rose strong novaseq sale offset
expect declin hiseq instrument expect robust consum sale
throughout year ilmn client base expand approxim
novaseq instrument order came new custom
straight-from-benchtop util lower throughput
instrument past also see continu demand hiseq
custom transit novaseq also see benefit
increas nih budget /jeffrey loo cfa
analyst research note compani news
et cfra maintain hold opinion share inc
lower target price ep
estim long-term averag forward price-to-earnings due slow growth
ep vs miss consensu maintain ep
estim revenu grew yoy mark
materi slowdown growth first month part
deceler relat china custom pull order
ahead tariff take effect concern us though rapidli
rise expens especi sg increas yoy
higher expens contribut yoy declin adjust pre-tax incom
full year sale growth expect slowdown around
growth novaseq upgrad cycl matur continu think
attract growth prospect maintain leadership rapidli
grow sequenc market remain neutral due caution premium
pm et cfra maintain hold opinion share inc
lower target price
ep estim line long-term histor forward price-to-earnings averag
rais ep estim
present jpmorgan health confer yesterday close
report revenu grew yoy cap cy revenu
growth growth materi slowdown yoy growth
first nine month year also forecast revenu growth
rang market reaction revenu guidanc
neg share around mid-day expect sale
growth cool impress growth howev revenu
tend somewhat cyclic new product launch novaseq
system upgrad approach two-year anniversari lower valuat
multipl think investor expect rein follow new
et cfra maintain hold opinion share inc
lower target price
ep estim line forward price-to-earnings averag rais
ep estim initi ep
vs handili beat consensu perform quarter
impress usual sale yoy due rapid growth
histori howev mark slowdown growth rate averag yoy
prior three quarter unexpect nearli two
year remov last major tech upgrad novaseq system
launch spur recent growth acceler admir
ilmn domin posit sequenc outstand oper
perform op margin bp yoy note latest growth cycl
produc sale growth consecut quarter versu
consecut last unusu increas size
warrant lower valuat view /colin scarola
buy maintain target price
ep estim materi averag
roughli premium due acceler growth expect
uptak next gener sequenc system maintain
ep estim sale
yoy sharp acceler growth rate
respect encourag perform particularli
strong demand seen newest novaseq system
replac last gener system sale strength driven share
year-to-d price-to-earnings ntm earn forecast level last
seen summer previou gener upgrad cycl peak
price eclips fall even sale growth remain
robust period think busi outlook remain
strong cautiou valuat given ever-high expect
growth /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
